¹û¶³ÊÓƵ

Phase 1 trial is evaluating the safety and tolerability of a novel formulation of intranasal 5-MeO-DMT Study will measure detailed pharmacokinetics and metabolism of 5-MeO-DMT in healthy volunteers Preliminary data, expected H1 2022, to support Phase 2 study designs investigating the use of 5-MeO-DMT in treatment resistant depression (TRD) and other neuropsychiatric indications

The Psychedelics as Medicine Report: Third Edition provides unparalleled consumer insights and market intelligence from experts and industry leaders, helping investors cut through the noise and identify real opportunities.

World-first phase 1 trial will evaluate efficacy of psilocybin in Short-lasting Unilateral Neuralgiform Headache Attacks (SUNHA) Data expected in early 2022 SUNHA, a rare and debilitating headache condition, is estimated to affect 40,000 patients in US and Europe

Upsized and oversubscribed Series B financing brings healthcare and science focused venture capital Aims to support acceleration of clinical development of low-dose psilocybin in SUNHA and 5MeO-DMT in other neuro-psychiatric indications

There are incredible breakthroughs being made right now by life sciences companies, which are exploring and developing new compounds with the potential to transform mental health treatment. But new drugs are just part of the solution.

We continue our look back at the heritage of the ¹û¶³ÊÓƵ Foundation’s ground-breaking research programmes and the potential for ¹û¶³ÊÓƵ, which leverages the Foundation’s knowledge and research capabilities through a close strategic partnership. This latest instalment of the Science Explained series examines the link between the acute psychedelic experience and longer-term changes.

¹û¶³ÊÓƵ’s CEO Cosmo Feilding Mellen comments on 5-MeO-DMT’s potential to rival psilocybin as a cost-effective psychedelic treatment for depression and addiction.

From magic mushrooms to ketamine, psychedelic drugs are having a serious heyday across the planet. Currently seeing considerable interest and acceptance by the public to treat emotional distress, the so-called third wave of psychedelics is cresting. And with that swelling attention is the creation of the essential machinery to support the new medical model — including consistent protocols and training preparation for clinicians.

¹û¶³ÊÓƵ, a private company dedicated to addressing neurological and psychiatric disorders through psychedelic medicine, has appointed ex-GW Pharmaceuticals CFO Adam George as a director with immediate effect.

¹û¶³ÊÓƵ, a private company dedicated to addressing neurological and psychiatric disorders through psychedelic medicine, has appointed ex-GW Pharmaceuticals CFO Adam George as a director with immediate effect.